Day 1 | Thursday, November 10, 2016

8:30 Registration & Continental Breakfast, Glover Park Ball Room
8:50 Welcome & Opening Remarks

SESSION I | LESION GENESIS & THERAPEUTIC TARGETS

Moderator – Doug Marchuk, Duke University

9:00 High-throughput screening: An approach for potential therapies for CCM
Angeliki, Louvi, Yale School of Medicine, New Haven, CT

9:20 KRIT1 loss-of-function sensitizes cells to oxidative stress- and inflammation-mediated molecular and cellular dysfunctions by affecting major redox-sensitive mechanisms: towards a unifying mechanistic scenario for CCM disease pathogenesis and treatment
Francesco Retta, University of Torino, Torino, Italy

9:40 Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signaling
Alan Tang, University of Pennsylvania, Philadelphia PA

10:00 Augmented exocytosis and angiopoietin-2 secretion contribute to cerebral cavernous malformations
Huanjiao Jenny Zhou, Yale University School of Medicine, New Haven, CT

10:20 DISCUSSION
10:40 DISCUSSION & BREAK

SPECIAL SESSION | TRAINEE PLENARY PRESENTATION

10:50 Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations
Miguel Alejandro Lopez-Ramirez, UCSD, San Diego, CA

11:30 GROUP PHOTO & BREAK

12:00 LUNCH – Café Dupont

SESSION II | BIOMARKERS & CLINICAL TRIALS

Moderator – Issam Awad, University of Chicago

1:00 Plasma Biomarkers of inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations
Romuald Girard, University of Chicago, Chicago, IL

1:20 Brain Lesion Count in Familial Cerebral Cavernous Malformation Type 1 (CCM1) Patients is Associated with Risk of Intracranial Hemorrhage
Jeffrey Nelson, UCSF, San Francisco, CA

1:40 Differential Expression of Immunoglobulin Genes in Blood and Lesion Burden in Familial Cerebral Cavernous Malformation Type 1 (CCM1) Patients
Helen Kim, UCSF, San Francisco, CA

2:00 Investigating the potential of BA-1049 for treatment of CCM
Lisa McKerracher, BioAxone BioSciences Inc., Cambridge, MA

2:20 A proposed trial of oral propranolol for symptomatic cerebral cavernous malformation not amenable to surgical resection
Yashar Kalani, University of Utah School of Medicine, Salt Lake City, UT

2:40 DISCUSSION

3:00 BREAK (END OF DAY 1 REGULAR SESSIONS)
SPECIAL SESSION | CLINICAL TRIAL READINESS (3:15 – 5 PM)

Moderated by Amy Akers & Connie Lee, Angioma Alliance

Connie Lee – Patient community needs & considerations for recruitment/enrollment
Jim Koenig – NIH requirements for trial funding
Helen Kim – Design considerations and questions
Kelly Flemming – Clinical data elements
Blaine Hart – Imaging data elements
Issam Awad – Biomarkers and their validation
Michael Lawton – Treatment vs follow-up; outcomes
Lisa McKerracher – Industry needs to move to Phil/II

POSTER SESSION | FOXHALL BALLROOM (4:30-6 PM)

BA-1049 reverses ROCK activation in brain
Matthew Abbinanti, BioAxone BioSciences, Inc. Cambridge, MA

Behavioral and Emotional Difficulties and Family Burden in Children and Adolescents with Cerebral Cavernous Malformations
Savannah Cheek, University of New Mexico, Albuquerque, NM

Is the common CCM2 exon 2-10 deletion due to a founder mutation in the US population?
Matthew Detter, Duke University, Durham, NC

MRI Sequence Sensitivity for the Detection of Spinal Cavernous Malformations
Blaine Hart, University of New Mexico, Albuquerque, NM

Genome-wide sequencing reveals differentially expressed microRNAs in Cerebral Cavernous Malformations
Souvik Kar, International Neuroscience Institute, Hannover, Germany

Micro-Computed Tomography in Murine Models of CCM as a Paradigm for Brain Disease
Thomas Moore, University of Chicago, Chicago, IL

Human brain endothelial cell ROCK1/2 protein interactions
Michael Moritz, UCLA David Geffen School of Medicine, Los Angeles, CA

Genetic Inactivation of RhoA-kinase in Ccm3+/− mice suggest a role for the RhoA-kinase pathway in CCM3-lesion genesis and maturation
Amy Peiper, Duke University, Durham, NC

Cerebrovascular angiomotin mediates convergent CCM protein signaling
Taline S. Shishoian, UCLA David Geffen School of Medicine, Los Angeles, CA

UK Priorities for Research into Cavernoma
David White, Caveroma alliance UK

WELCOME DINNER | THE GRYPHON RESTAURANT (6:30 - 9 PM)

The Gryphon, 1337 Connecticut Avenue, NW

2016 CCM Scientific Meeting Welcome Dinner is Sponsored by DSG, Inc. (Document Solutions Group)
Day 2 | Friday, November 11, 2016

SESSION III | THINKING outside the brain – CCM MECHANISMS

Moderated by Angeliki Louvi, Yale

9:00  Deciphering the roles of CCM proteins inside and outside the CCM-pathway
Claudia Jasmin Rödel, University of Potsdam, Potsdam, Germany

9:20  C. elegans CCM-3 mediated PARtitioning is crucial for germline lumen formation and embryo development
Swati Pal, The Hospital for Sick Children, Toronto, Ontario

9:40  KLF4 overexpression due to the loss of CCM genes results in congenital heart disease with outflow tract defects
Kevin Whitehead, University of Utah, Salt Lake City, UT

10:00  DISCUSSION & BREAK

SPECIAL SESSION | INVITED KEYNOTE ADDRESS

10:30  Vascular Disease and the Mouse Model – Lessons from HHT Investigations
S. Paul Oh, Professor of Physiology and Functional Genomics, University of Florida, Gainesville, FL

11:30  BREAK

12:00  LUNCH & TRAINEE NETWORKING SESSION

SESSION IV | IMAGING & MOUSE MODELS

Moderated by Kevin Whitehead, University of Utah

12:40  Vertebral Hemangiomas in a CCM1 population
Blaine Hart, University of New Mexico, Albuquerque, NM

1:00  Micro-CT imaging of cerebral cavernous malformations in mouse models
Jaesung Choi, Centenary Institute & Sydney Medical School, Sydney, Australia

1:20  Phenotypic Features of Murine Models of Cerebral Cavernous Malformations
Issam Awad, University of Chicago, Chicago, IL

1:40  DISCUSSION & BREAK

DISCUSSION | CCM & CANCER: OVERLAPPING BIOLOGY & CROSS-FERTILIZATION (2-3:30 PM)

Moderated by Brent Derry, SickKids Hospital

Anne-Claude Gingras –Protein Networks  Maria Grazia Lampugnani – EndMT
Angela Glading – Adhesion & Permeability  Brad St. Croix – Angiogenesis & Cancer